-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] With the continuous implementation of a series of medical reform policies such as volume-based procurement, the pharmaceutical industry is about to change, and structural differentiation is becoming more and more obvious.
Innovative drugs, medical devices, and biological products are gradually becoming the main growth drivers for the development of the industry
.
It should be noted that, at the same time, the importance of independent and controllable industrial chain is becoming more and more prominent, and more and more pharmaceutical companies have begun to join the ranks of the entire industrial chain
.
The importance of independent and controllable pharmaceutical industry chain is constantly highlighted! (Photo source: Pharmaceutical Network) For example, on August 9, Dorui Medicine announced that the company intends to acquire a 40% stake in Bozhou Tianji held by Hubei Tianji
.
For the purpose of this acquisition, Dorui Medicine stated that it is conducive to accelerating the improvement of the company's traditional Chinese medicine industry layout and further enhancing the company's profitability
.
It is understood that Sinopharm Group has been accelerating the layout of the entire Chinese medicine industry chain through restructuring and integration in recent years
.
From 2012 to 2021, it successively acquired Yingtian Pharmaceutical, Tongjitang, Tianjiang Pharmaceutical and Yifang Pharmaceutical; and strategically reorganized Taiji Group.
.
.
According to the data, by the end of 2021, it has achieved an asset scale of 54.
605 billion yuan and achieved operating income.
32.
755 billion yuan, net profit of 2.
069 billion yuan, and a 10-year profit compound growth rate of 65.
7%
.
Starting from the third quarter of 2021, WuXi PharmaTech has also adjusted the organizational structure of the company's business segments, integrating end-to-end integrated service capabilities into the three new business segments of chemistry, biology, and testing
.
At present, it has five business segments: chemical business segment, biology business segment, testing business segment, cell and gene therapy, and domestic new drug research and development service department
.
Today, the five business segments have begun to exert platform synergy, and its unique CRDMO and CTDMO business models are driving the company to accelerate its development
.
In addition, Jiudian Pharma has long been insisting on investing in R&D innovation ahead of time and striving to build a complete industrial chain to enhance its competitive advantage
.
It is understood that Jiudian Pharmaceutical pursues comprehensive supporting advantages in the construction of the industrial chain, and is committed to the integrated development of "pharmaceutical preparations + raw materials + pharmaceutical excipients".
The ointment is made into preparations to form a complete industrial chain from raw materials to preparations, extraction of traditional Chinese medicines to proprietary Chinese medicines
.
It is worth noting that, from an overall perspective, under the background of in-depth layout of the industry chain by pharmaceutical companies, the upstream of the pharmaceutical industry chain, including biopharmaceutical pharmaceutical equipment and consumables, life science products and services, imaging equipment, etc.
are also concerned by pharmaceutical companies.
focus
.
In this regard, the industry believes that strengthening cooperation with upstream manufacturers will help pharmaceutical companies to strengthen the quality control of products and equipment from the source
.
In the future, under this background, many industries in the industrial chain will usher in opportunities, among which, the prosperity of pharmaceutical equipment is expected to increase rapidly
.
Pharmaceutical equipment is the production machinery used in the pharmaceutical workshop, which is an indispensable part in the pharmaceutical industry
.
Therefore, the industry predicts that in the future, under the background of enterprises accelerating the construction of a complete industrial chain, it will continue to provide rare opportunities for the future development of China's pharmaceutical equipment industry.
At the same time, enterprises in the industry will also develop in a more diversified direction, and the competition pattern will be Continue to improve
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Innovative drugs, medical devices, and biological products are gradually becoming the main growth drivers for the development of the industry
.
It should be noted that, at the same time, the importance of independent and controllable industrial chain is becoming more and more prominent, and more and more pharmaceutical companies have begun to join the ranks of the entire industrial chain
.
The importance of independent and controllable pharmaceutical industry chain is constantly highlighted! (Photo source: Pharmaceutical Network) For example, on August 9, Dorui Medicine announced that the company intends to acquire a 40% stake in Bozhou Tianji held by Hubei Tianji
.
For the purpose of this acquisition, Dorui Medicine stated that it is conducive to accelerating the improvement of the company's traditional Chinese medicine industry layout and further enhancing the company's profitability
.
It is understood that Sinopharm Group has been accelerating the layout of the entire Chinese medicine industry chain through restructuring and integration in recent years
.
From 2012 to 2021, it successively acquired Yingtian Pharmaceutical, Tongjitang, Tianjiang Pharmaceutical and Yifang Pharmaceutical; and strategically reorganized Taiji Group.
.
.
According to the data, by the end of 2021, it has achieved an asset scale of 54.
605 billion yuan and achieved operating income.
32.
755 billion yuan, net profit of 2.
069 billion yuan, and a 10-year profit compound growth rate of 65.
7%
.
Starting from the third quarter of 2021, WuXi PharmaTech has also adjusted the organizational structure of the company's business segments, integrating end-to-end integrated service capabilities into the three new business segments of chemistry, biology, and testing
.
At present, it has five business segments: chemical business segment, biology business segment, testing business segment, cell and gene therapy, and domestic new drug research and development service department
.
Today, the five business segments have begun to exert platform synergy, and its unique CRDMO and CTDMO business models are driving the company to accelerate its development
.
In addition, Jiudian Pharma has long been insisting on investing in R&D innovation ahead of time and striving to build a complete industrial chain to enhance its competitive advantage
.
It is understood that Jiudian Pharmaceutical pursues comprehensive supporting advantages in the construction of the industrial chain, and is committed to the integrated development of "pharmaceutical preparations + raw materials + pharmaceutical excipients".
The ointment is made into preparations to form a complete industrial chain from raw materials to preparations, extraction of traditional Chinese medicines to proprietary Chinese medicines
.
It is worth noting that, from an overall perspective, under the background of in-depth layout of the industry chain by pharmaceutical companies, the upstream of the pharmaceutical industry chain, including biopharmaceutical pharmaceutical equipment and consumables, life science products and services, imaging equipment, etc.
are also concerned by pharmaceutical companies.
focus
.
In this regard, the industry believes that strengthening cooperation with upstream manufacturers will help pharmaceutical companies to strengthen the quality control of products and equipment from the source
.
In the future, under this background, many industries in the industrial chain will usher in opportunities, among which, the prosperity of pharmaceutical equipment is expected to increase rapidly
.
Pharmaceutical equipment is the production machinery used in the pharmaceutical workshop, which is an indispensable part in the pharmaceutical industry
.
Therefore, the industry predicts that in the future, under the background of enterprises accelerating the construction of a complete industrial chain, it will continue to provide rare opportunities for the future development of China's pharmaceutical equipment industry.
At the same time, enterprises in the industry will also develop in a more diversified direction, and the competition pattern will be Continue to improve
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
